The global angina pectoris drugs market size was valued at USD 8.5 Billion in 2016 and is expected to grow at a CAGR of 3.2% during the forecast period. The U.S. dominated the angina pectoris drugs market among the seven major countries. The global angina pectoris market is expected to be collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare, and availability of effective treatment methods across the emerging markets.
Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as - stable, unstable, microvascular, and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society, and ability to work.
Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from the American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris. We estimate the annual risk of associated non-fatal myocardial infarction (MI) and death at 3% and 1.0-2.0% respectively. The prevalence of angina rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74 and from 0.1- 1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74.
The angina pectoris drug market is commercially meaningful, however, branded sales are in decline as generics dominate a larger portion of prescriptions. Though the market is fragmented, key players such as Sanofi, Gilead, AstraZeneca, and Pfizer hold significant market positions. Rising geriatric population in territories such as China will influence the demand for angina pectoris drugs in the coming years.
The drug space can be divided into various therapeutic classes such as Beta Blockers, Calcium Antagonists, Anti-Platelets, Anticoagulants, Nitrates, and Ranolazine. The Beta-Blocker market now is predominately generic with key patent expirations impacting GlaxoSmithKline’s Coreg and AstraZeneca’s Toprol. Post Pfizer’s Norvasc patent being determined invalid in 2007, the Calcium Antagonist market is predominantly generic as well.
Novel targets and therapies gaining traction include Factor Xa Inhibitors, monoclonal antibodies, and gene therapy. Some prominent players covered in the segment include Amgen, Taxus Cardium Pharmaceuticals, LegoChem Biosciences, Lee’s Pharmaceutical Holdings, Milestone Pharmaceuticals, Juventas Therapeutics, ViroMed, and Kuhnil Pharmaceutical.
Changing regulatory scenario in the U.S. and EU is anticipated to impact clinical trials of Advanced Therapy Medicinal Products. Multiple gene therapy products in Phase II/III trials are emerging as a novel approach towards addressing the need for non-surgical cardiovascular treatments. Taxus Cardium’s adenovector (serotype 5) DNA-based gene therapy is undergoing late-stage clinical trials and could present promising growth opportunities for the market in the next few years.
The U.S. dominated the space by accounting for more than 33.0% of the market share in 2016. Established healthcare infrastructure, increased adoption of therapeutics, and presence of key manufacturers in the U.S. are responsible for its large share. Moreover, increasing incidence of cardiac disorders due to sedentary lifestyle and favorable regulatory initiatives are fueling the market growth.
China offers strong opportunity for market expansion due to removal of price caps on all medicine categories, the ongoing Healthy China 2020 healthcare reform, and supportive 12th Five-Year Plan measures that target biotechnology as key development sector. Furthermore, presence of a large target population and strong unmet clinical needs are some of the factors that are expected to propel the growth of this region.
Some of the key players operating in this industry are Sanofi, Gilead, AstraZeneca, Pfizer, Eli Lilly, Amgen, and GlaxoSmithKline. The companies are focusing on business expansion in emerging markets or developing regions such as China by adopting strategies including mergers & acquisitions for the development of new products.
Biosimilar development is emerging as a promising market opportunity in angina therapeutics. Multiple enoxaparin sodium and abciximab biosimilars have gained approvals in the U.S., European and Indian markets.
Report Attribute |
Details |
Market size value in 2020 |
USD 9.6 billion |
Revenue forecast in 2022 |
USD 10.6 billion |
Growth Rate |
CAGR of 3.2% from 2017 to 2022 |
Base year for estimation |
2016 |
Historical data |
2014 - 2016 |
Forecast period |
2017 - 2022 |
Quantitative units |
Revenue in USD Million & CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Therapeutic class, pipeline, region |
Country scope |
U.S.; U.K.; Germany; Spain; Italy; France; Japan |
Key companies profiled |
Amgen; Inc.; Sanofi S.A.; Gilead Sciences; Inc.; AstraZeneca Plc; GlaxoSmithKline Plc.; Eli Lilly and Company; Pfizer; Inc.; Novartis AG; XyloCor Therapeutics; Inc.; Tasly Pharmaceuticals; Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report provides an analysis of the market trends in each sub-category as well as forecasts revenue growth from 2014 to 2022. For this study, Grand View Research has segmented the angina therapeutics market based on therapeutic class:
Therapeutic Class Outlook (% market share; 2016 - 2022)
Beta Blockers
Calcium Antagonists
Anticoagulants
Anti-Platelets
Others
Nitrates
Anti-anginal (Ranolazine)
ACE inhibitors
Regional Outlook (% market share; 2016 - 2022)
The U.S.
U.K.
France
Germany
Italy
Spain
Japan
b. The global angina pectoris drugs market size was estimated at USD 9.3 billion in 2019 and is expected to reach USD 9.6 billion in 2020.
b. The global angina pectoris drugs market is expected to grow at a compound annual growth rate of 3.2% from 2016 to 2022 to reach USD 10.6 billion by 2022.
b. The U.S. dominated the angina pectoris drugs market with a share of 33.8% in 2019. This is attributable to the high adoption of angina pectoris therapies, presence of prominent players, and increasing R&D investments for the development of novel therapies.
b. Some key players operating in the angina pectoris drugs market include Amgen, Inc., Sanofi S.A., Gilead Sciences, Inc., AstraZeneca Plc, GlaxoSmithKline Plc., Eli Lilly and Company, Pfizer, Inc., Novartis AG, XyloCor Therapeutics, Inc., and Tasly Pharmaceuticals, Inc.
b. Key factors that are driving the market growth include high prevalence of angina pectoris, increasing R&D investments, and strategic initiatives by major players.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.